Mission Statement, Vision, & Core Values (2026) of Shilpa Medicare Limited.

Born in 1987, Shilpa Medicare Limited has grown into a global pharmaceutical force exporting to over 100 countries and operating manufacturing sites certified by regulators such as US FDA, EUGMP, PMDA, TGA and MHRA, with a product mix that emphasizes oncology and specialty therapeutics while spanning generics, APIs and CDMO services; guided by a mission to deliver the highest quality medicines at affordable prices and a vision of continuous system improvement with environmental responsibility, the company's core values-Integrity, Innovation, Quality, Collaboration and Customer Focus-drive R&D, compliance and digital transformation initiatives, and were further manifested when Shilpa Medicare entered a strategic joint venture in August 2025 with Saudi PPI to localize pharmaceutical manufacturing in support of Vision 2030.

Shilpa Medicare Limited (SHILPAMED.NS) - Intro

• Founded: 1987
• Global reach: Exports to >100 countries
• Regulatory certifications: US FDA, EUGMP, PMDA, TGA, MHRA
• Business lines: Generic formulations, APIs, biosimilars, CDMO
• Strategic focus: Oncology and specialty therapeutics

• Quality First - uncompromising adherence to GMP and regulatory expectations.
• Patient Centricity - development decisions guided by patient access and safety.
• Innovation & Collaboration - investing in R&D, CDMO partnerships and tech adoption.
• Integrity & Compliance - ethical conduct across manufacturing, clinical and commercial operations.
• Sustainability & Local Impact - building capacity that supports regional healthcare security.

• Regulated markets expansion - continued filings and registrations for US, EU and Japan.
• CDMO growth - scaling contract development and manufacturing to serve global innovators.
• Oncology pipeline - prioritizing generics and biosimilars in oncology and specialty care.
• Digital transformation - deploying automation, data analytics and digital quality systems to raise OEE and compliance traceability.
• International manufacturing footprint - strategic JV to localize production in priority markets.

• Market listing: National Stock Exchange - ticker SHILPAMED.NS
• Capital allocation: sustained investments into manufacturing scale-up and regulated market filings (multi-year program)
• Partnership-driven expansion: the Aug 2025 JV with Saudi-based Pharma Pharmaceutical Industries & Biological Products (PPI) supports alignment with Saudi Vision 2030 by localizing pharmaceutical manufacturing and diversifying supply chains.

• Product strategy - prioritize generics and biosimilars with high unmet need in oncology, supported by targeted R&D and formulation capabilities.
• Quality systems - maintain and expand approvals to enter and sustain presence in regulated markets.
• Global footprint - combine exports with localized production (e.g., Saudi JV) to improve market access and regulatory responsiveness.
• Operational excellence - leverage digital transformation to increase throughput, reduce batch cycle times and strengthen compliance reporting.

Shilpa Medicare Limited (SHILPAMED.NS) - Overview

Mission Statement

Shilpa Medicare's mission is to provide patients worldwide with access to the highest quality medicines at affordable prices. This patient-centric commitment drives the company to overcome economic and regulatory barriers so essential therapies reach those in need. The mission guides all functions-from R&D to manufacturing, quality assurance and distribution-ensuring alignment with international regulatory standards and continuous improvement in product quality and affordability.

• Patient-first orientation: prioritize patient well-being in strategic and operational decisions.
• Affordability focus: develop cost-effective manufacturing and supply solutions to lower treatment costs.
• Quality compliance: maintain GMP, WHO, and major regulatory standards across manufacturing sites.
• Global access: expand therapeutic reach across developed and emerging markets through exports and partnerships.

Vision

To be a globally trusted specialty pharmaceutical company known for delivering high-quality, affordable therapies-particularly in oncology, cardiology, and niche generics-while continuously innovating to address evolving patient needs worldwide.

• Global footprint expansion with emphasis on regulated markets.
• Leadership in selected therapeutic segments through differentiated products and complex generics.
• Scaling sustainable operations with investments in green chemistry and energy-efficient manufacturing.

Core Values

• Integrity: transparent conduct across R&D, regulatory filings, and commercial interactions.
• Excellence: relentless quality control, continuous process improvement and compliance.
• Innovation: invest in novel formulations, delivery systems and complex molecule expertise.
• Affordability & Access: pricing strategies and partnerships to broaden patient access.
• Collaboration: cross-functional teamwork and external alliances with academia and global partners.
• Sustainability: minimize environmental footprint and ensure responsible supply chain practices.

Operational and Strategic Metrics

Key business metrics and recent financial indicators (annualized / most recent reported figures):

Strategic Pillars Aligned to the Mission

• Therapeutic focus: prioritize oncology, anti-infectives and complex generics to meet unmet needs.
• Regulated market entry: secure ANDA/NDA approvals and quality certifications for wider access.
• Cost-efficient manufacturing: leverage scale and technology to reduce unit costs and pass savings to patients.
• Partnerships & licensing: co-develop and out-license niche formulations to accelerate reach.
• Sustainability integration: adopt energy-efficient processes and waste minimization to ensure long-term supply reliability.

For deeper investor-focused context and shareholder activity around the company, see: Exploring Shilpa Medicare Limited Investor Profile: Who's Buying and Why?

Shilpa Medicare Limited (SHILPAMED.NS) - Mission Statement

• Quality & Compliance: Achieve and maintain global regulatory approvals (WHO-GMP, EU/US-equivalent standards) across all manufacturing sites.
• Continuous Improvement: Institutionalize process improvements (Lean/Six Sigma) to reduce batch deviations and improve on-time delivery.
• Environmental Health: Reduce emissions, effluent load and energy intensity per unit produced while increasing use of renewable energy.
• Access & Affordability: Scale production of essential generics and specialty APIs to lower per-unit costs and expand patient access globally.
• Innovation: Invest in R&D for new formulations, controlled substances, and oncology/dermatology segments to diversify product mix.

• Maintain the best quality by continuously improving systems to ensure regulatory compliance and meet international standards, while also considering environmental health.
• Embed continuous improvement culture to drive operational excellence, reduce cycle-times, and support faster regulatory submissions.
• Integrate sustainability goals (effluent treatment, carbon footprint reduction, resource efficiency) into manufacturing and supply-chain decisions.
• Align product portfolio and pricing strategies to deliver affordable healthcare solutions that positively impact patient health and well‑being.

• Quality-first manufacturing: Capital allocation prioritizes GMP upgrades, automated QA lines, and digital batch-record systems to reduce deviations and time-to-approval.
• Regulatory roadmap: Dedicated regulatory teams map submissions to stringent markets, shortening approval cycles and expanding addressable markets.
• Sustainable operations: Investments in effluent treatment, solvent recovery, and renewable energy to minimize environmental footprint per unit produced.
• R&D & pipeline: Focus on specialty generics, niche APIs and formulation technologies to move up the value chain and protect margins.
• Commercial access: Pricing strategies and partnerships to increase availability of key therapies at affordable price points in emerging markets.

• Investments and metrics are prioritized to ensure regulatory compliance and product quality, directly supporting patient safety and access.
• Environmental initiatives reduce long-term operational risk while meeting stakeholder expectations for sustainable manufacturing.
• Targeted R&D and commercial strategies aim to balance affordable pricing with healthy margins, ensuring reinvestment capacity.

Shilpa Medicare Limited (SHILPAMED.NS) - Vision Statement

• Integrity: Upholding the highest ethical standards and transparency across manufacturing, regulatory submissions, and commercial activities to build long-term stakeholder trust.
• Innovation: Investing consistently in R&D and advanced technologies to develop differentiated molecules, injectable formulations, and targeted therapies that strengthen the company's competitive edge.
• Quality: Delivering products that meet international regulatory norms (WHO-GMP, US FDA/other approvals where applicable) and exceed customer expectations through robust quality management systems.
• Collaboration: Fostering cross-functional teamwork and strategic partnerships with research institutes, CROs, and global distributors to accelerate product development and market access.
• Customer Focus: Anticipating and responding to patient and customer needs with agility, professional service, and reliable supply chains.

• Scale R&D to advance specialty molecules and complex generics, aiming to convert pipeline assets into commercial launches within projected timelines.
• Strengthen regulatory affairs and quality assurance to maintain export growth and secure approvals from major health authorities.
• Enhance manufacturing capacity and supply-chain resilience to guarantee timely deliveries and meet rising global demand.
• Embed ethical governance across corporate functions to preserve stakeholder trust and transparent reporting.
• Deepen customer engagement through tailored service models for institutional, retail, and international partners.

• R&D spend as % of revenue (target: maintain or increase from ~6%).
• Year-on-year export revenue growth (target: double-digit CAGR over medium term).
• Quality metric: regulatory audit pass rate and zero critical recalls.
• Employee engagement and retention (target: reduce voluntary attrition below industry average).